Suppr超能文献

用于慢性开角型青光眼治疗的XEN凝胶支架:文献综述

XEN Gel Stent for management of chronic open angle glaucoma: A review of the literature.

作者信息

Buffault J, Baudouin C, Labbé A

机构信息

Service d'ophtalmologie, centre hospitalier national d'ophtalmologie des Quinze-Vingts, IHU ForeSight, , 28, rue de Charenton, 75012 Paris, France.

Service d'ophtalmologie, centre hospitalier national d'ophtalmologie des Quinze-Vingts, IHU ForeSight, , 28, rue de Charenton, 75012 Paris, France; Service d'ophtalmologie, hôpital Ambroise-Paré, université de Versailles Saint-Quentin-en-Yvelines, AP-HP, 9, avenue Charles-De-Gaulle, 92100 Boulogne-Billancourt, France; Inserm, U968, université UPMC Paris VI, UMR S 968, institut de la vision, CNRS, UMR 7210, 75012 Paris, France.

出版信息

J Fr Ophtalmol. 2019 Feb;42(2):e37-e46. doi: 10.1016/j.jfo.2018.12.002. Epub 2019 Jan 22.

Abstract

PURPOSE

The purpose of this study was to analyze the change in intraocular pressure (IOP) and glaucoma medications using the XEN Gel Stent as a solo procedure or in association with phacoemulsification in patients with chronic open angle glaucoma (OAG).

METHODS

We included cohort studies with at least one year of follow-up in patients with primary open angle glaucoma (POAG), pseudo-exfoliative glaucoma (PXG) or pigmentary glaucoma (PG) who received a XEN gel stent. The main outcome measure was IOP reduction at 12 months follow-up. Secondary outcomes were the decrease in glaucoma medications 12 months after surgery, frequency and type of postoperative interventions and complication rate.

RESULTS

A total of 8 case series published between 2016 and 2018 were included; six were prospective studies, and two were retrospective. There was no randomized controlled trial. The data concerned a total of 958 eyes of 777 patients. The various studies showed a mean IOP at 12 months between 13 and 16mmHg, which represented an IOP reduction between 25 and 56% (mean: 42%). This decrease was associated with a reduction in glaucoma medications in all studies. The decrease in IOP was significantly greater in XEN implantation as a stand-alone procedure (44%) than in combined surgery (32%) (P<0.05). Transient hypotony (< 1 month) (3%), choroidal detachment or choroidal folds (1.5%), hyphema (1.9%), bleb leak (1.1%) and shallow anterior chamber (1.1%) were the most frequent complications. As for severe complications, four cases of malignant glaucoma (0.4%) and one case of retinal detachment have been reported. In the follow-up period, needling has been required in 32% of cases, and a total of 55 eyes (5.7%) required repeat filtering surgery or cyclodestructive procedure.

CONCLUSION

XEN Gel Stent appears effective for reducing IOP and the number of medications in OAG patients within 1 year postoperatively with an acceptable safety profile. However, vigilant postoperative follow-up and frequent postoperative maneuvers are required.

摘要

目的

本研究旨在分析在慢性开角型青光眼(OAG)患者中,单独使用XEN凝胶支架或与白内障超声乳化术联合使用时,眼内压(IOP)和青光眼药物的变化情况。

方法

我们纳入了对接受XEN凝胶支架治疗的原发性开角型青光眼(POAG)、假性剥脱性青光眼(PXG)或色素性青光眼(PG)患者进行至少一年随访的队列研究。主要观察指标为随访12个月时的眼压降低情况。次要观察指标为术后12个月青光眼药物的减少情况、术后干预的频率和类型以及并发症发生率。

结果

共纳入2016年至2018年间发表的8个病例系列;其中6个为前瞻性研究,2个为回顾性研究。没有随机对照试验。数据涉及777例患者的958只眼睛。各项研究显示,12个月时的平均眼压在13至16mmHg之间,眼压降低了25%至56%(平均:42%)。在所有研究中,这种降低与青光眼药物的减少相关。单独植入XEN时眼压的降低(44%)显著大于联合手术(32%)(P<0.05)。短暂性低眼压(<1个月)(3%)、脉络膜脱离或脉络膜皱褶(1.5%)、前房积血(1.9%)、滤过泡渗漏(1.1%)和浅前房(1.1%)是最常见的并发症。至于严重并发症,报告了4例恶性青光眼(0.4%)和1例视网膜脱离。在随访期间,32%的病例需要进行针刺治疗,共有55只眼睛(5.7%)需要重复滤过手术或睫状体破坏手术。

结论

XEN凝胶支架在术后1年内似乎能有效降低OAG患者的眼压并减少药物使用量,且安全性可接受。然而,术后需要进行密切随访和频繁的术后处理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验